Business News • PR NewsWire • Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID

Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID

Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID

SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the top-line results from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI) were presented today at the 20th Annual European Congress of Clinic

View More : http://www.prnewswire.com/news-releases/positive-results-from-optimer-pharmaceuticals-second-phase-3-study-of-fidaxomici...

Releted News by prnewswire

Cempra Pharmaceuticals Presents New Data on Its Multi-Drug Resistant Anti-Infective Portfolio, CEM-101 and TAKSTA(TM) (CEM-102), at the 20th European Congress of Clinical Microbiology and Infectious Disease

Teamsters Protest Honda at NY Auto Show

'VH1's Tough Love Couples' Get Frisky at Del Frisco's

Lowe's Partners With Phoenix International Raceway to Bring Kobalt Tools 500 to Track in November